9339 Results for "

Linker

" in MedChemExpress (MCE) Product Catalog:
Products (9339)

9339 Results for "Linker" in MCE Product Catalog:

14
14 Cited Publications
Cat. No.: HY-111373
CAS No.: 1887095-82-0
Purity:  99.92%
Target:  

mTOR Autophagy

Research Areas:  

Cancer

RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-101070
CAS No.: 1228105-51-8
Purity:  99.23%
Synonyms: DM1-SMCC
Research Areas:  

Cancer

SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-138298
CAS No.: 1826843-81-5
Purity:  98.90%
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Research Areas:  

Cancer

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-138298A
CAS No.: 1826843-81-5
Purity:  99.58%
Synonyms: T-DXd; DS-8201; DS-8201a
Research Areas:  

Cancer

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-132254
CAS No.: 1491917-83-9
Purity:  99.13%
Synonyms: IMMU-132
Research Areas:  

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-132254A
CAS No.: 1491917-83-9
Purity:  96.61%
Synonyms: IMMU-132 (solution)
Research Areas:  

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-18676
CAS No.: 2070015-22-2
Research Areas:  

Cancer

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain) . OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner . OSU-T315 causes cell death through apoptosis and autophagy .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-K0211

MCE Glutathione Agarose, a 4% highly cross-linked agarose reagent, enables high-yield, high-purity purification of GST-tagged proteins.

loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-K0214

MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.

loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-120217
CAS No.: 1448188-62-2
Purity:  99.64%
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

VH032 is a VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. VH032 is a VHL/HIF-1α interaction inhibitor with a Kdlinker to form PROTACs .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-107201
CAS No.: 7585-39-9
Purity:  99.95%
Synonyms: Betadex
Target:  

Influenza Virus

Research Areas:  

Infection

β-Cyclodextrin is a cyclic polysaccharide composed of seven units of glucose (α-D-glucopyranose) linked by α-(1,4) type bonds. β-Cyclodextrin has often been used to enhance the solubility of agents. β-Cyclodextrin has anti-influenza virus H1N1 activities.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-130458
CAS No.: 70539-42-3
Purity:  97.45%
Synonyms: EGS crossLinker
Target:  

PROTAC Linkers

Research Areas:  

Cancer

EGNHS is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-107608
CAS No.: 71160-24-2
Purity:  ≥98.0%
Synonyms: LTB4; 5(S),12(R)-DiHETE
Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15578
CAS No.: 863971-19-1
Purity:  99.96%
Synonyms: Maleimidocaproyl monomethylauristatin F
McMMAF (Maleimidocaproyl monomethylauristatin F) is a drug-linker conjugate for ADCs, formed by coupling the potent microtubule inhibitor Monomethyl auristatin F (MMAF) (HY-15579) with a maleimidocaproyl (mc) linker. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-42973
CAS No.: 1353016-71-3
Target:  

ADC Linkers

Research Areas:  

Cancer

DBCO-NHS ester is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-NHS ester is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-123943
CAS No.: 2138300-40-8
Target:  

STING

Research Areas:  

Cancer

STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC50) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-P9921A
CAS No.: 1018448-65-1
Synonyms: Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)
Research Areas:  

Cancer

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-17417
CAS No.: 357-08-4
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Naloxone hydrochloride is an orally active opioid receptor antagonist. Naloxone hydrochloride attenuates spinal cord stimulation‑associated anti‑hyperalgesic effects, antagonizes physiologic effects of endogenous opioid peptides linked to central nervous system injury sequelae, functions as a pressor agent to induce modest elevations in mean arterial blood pressure, exerts neuroprotective effects to improve post‑traumatic neurologic motor function, blocks opioid receptor‑mediated amnesic pathways, enhances memory consolidation, reverses Adrenocorticotropic hormone (ACTH) (HY-106373)- and epinephrine‑induced amnesia, and potentiates the memory‑facilitatory effects of ACTH and epinephrine .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-17417A
CAS No.: 465-65-6
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Naloxone hydrochloride is an orally active opioid receptor antagonist. Naloxone hydrochloride attenuates spinal cord stimulation‑associated anti‑hyperalgesic effects, antagonizes physiologic effects of endogenous opioid peptides linked to central nervous system injury sequelae, functions as a pressor agent to induce modest elevations in mean arterial blood pressure, exerts neuroprotective effects to improve post‑traumatic neurologic motor function, blocks opioid receptor‑mediated amnesic pathways, enhances memory consolidation, reverses Adrenocorticotropic hormone (ACTH) (HY-106373)‑ and epinephrine‑induced amnesia, and potentiates the memory‑facilitatory effects of ACTH and epinephrine .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-128946
CAS No.: 1279680-68-0
Purity:  99.07%
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .
loading...
    loading...